Aggrastat

(Tirofiban Hydrochloride)

Phase 3Small molecule

MMedicure

Aggrastat is one of 78 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeUnknown status

PreventionUnknown status

Ischemic StrokePhase 3

Unknown status

PreventionPreclinical

Unknown status

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Reminyl

WWim Janssens

Phase 3

1 2

Atorvastatin Calcium

Merck & Co.

Phase 3

1 3

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 4

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 5

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 6

Aggrastat

MMedicure

Phase 3

4 7

Zastaprazan

YYonsei University

Phase 3

1 8

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 9

SP-8203

SShin Poong Pharmaceutical Co. Ltd.

Phase 3

3 10

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke4 trials

Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke

Recruiting·—·Phase 3·NCT05604638·348 enrolled

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

Not yet recruiting·—·Phase 2/3·NCT06587347·302 enrolled

Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

Unknown status·—·Phase 2/3·NCT04491695·420 enrolled

Show 1 more trial

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

Withdrawn·UUniversity of Iowa·Phase 1/2·NCT04818944

Prevention2 trials

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT03406819·1,000 enrolled

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT03406832·1,000 enrolled

Aneurysm1 trial

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Completed·DDavid Hasan·Phase 1/2·NCT03691727·30 enrolled

Regulatory

FDA Approval Timeline[4]

May 14, 1998

AGGRASTAT

NDA NDA020912

May 17, 2002

AGGRASTAT

NDA NDA020913

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tirofiban Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tirofiban Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tirofiban Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020913). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Medicure company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedicure

Aggrastat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke4 trials

Prevention2 trials

Aneurysm1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News